Navigation Links
Isis Pharmaceuticals Reports Positive Phase 1 Data Demonstrating ISIS-APO(a) Rx Produces Significant Reductions in Lp(a) Levels
Date:11/16/2013

SIS-APO(a)Rx in patients with existing cardiovascular disease and high Lp(a) levels.  Individuals with high Lp(a) levels are at increased risk for cardiovascular events and need to substantially reduce their Lp(a).  We look forward to getting this program underway."

"Patients with high Lp(a) levels are at significant cardiovascular risk.  Unfortunately for these patients, current lipid-lowering drugs, such as statins, are unable to lower Lp(a) to recommended safe levels.  As such, new treatment approaches are needed.  As a patient with high Lp(a) and the president and founder of the Lipoprotein(a) Foundation, I am gratified with the increased emphasis in the cardiovascular community on Lp(a) and for the work that is being done on developing focused, targeted approaches to lowering Lp(a),"  said Sandra Revill Tremulis, president and founder of the Lipoprotein(a) Foundation.  "I am encouraged by the Phase 1 data presented today on ISIS-APO(a)Rx and hopeful that this approach to lowering Lp(a) could, for the first time, offer patients an effective, direct option to reducing their Lp(a)."

ISIS-APO(a)Rx is a wholly owned antisense drug targeting apolipoprotein(a) for the treatment of atherosclerosis.  Apolipoprotein(a) contributes to the formation of plaque in arteries through its attachment to an LDL-C particle in a complex called Lp(a).  High levels of Lp(a) are associated with an increased risk of atherosclerosis, coronary heart disease, heart attack and stroke.  While statins and other lipid-lowering drugs have a modest effect on lowering Lp(a), patients with elevated Lp(a) are unable to reach recommended safe Lp(a) levels.  ISIS-APO(a)Rx is designed to reduce Lp(a) by inhibiting the production of apolipoprotein(a).  Isis plans to develop ISIS-APO(a)Rx to treat patients with high Lp(a) levels who are at high ris
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Valeant Pharmaceuticals Announces Pricing Of Private Offering Of Senior Notes
2. Valeant Pharmaceuticals Announced Redemption Of $450 Million Aggregate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016
3. ANI Pharmaceuticals To Present At Oppenheimer 24th Annual Healthcare Conference On December 10, 2013
4. Ampio Pharmaceuticals to Present at Upcoming Investor Conference
5. DelMar Pharmaceuticals to Present Interim Clinical Data for VAL-083 in Glioblastoma at Society of Neuro-Oncology
6. Intercept Pharmaceuticals Reports Third Quarter 2013 Financial Results
7. Isis Pharmaceuticals Earns $1.5M from the Advancement of the Phase 2 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy
8. Actinium Pharmaceuticals Appoints Richard Steinhart As New Independent Director
9. Inovio Pharmaceuticals Reports 2013 Third Quarter Financial Results
10. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2013 Third Quarter Financial Results
11. GW Pharmaceuticals to Report 2013 Q4 and Full Year Financial Results and Host Conference Call on 19 November, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014  SiteOne Therapeutics Inc. ... equity financing. Led by Sears Capital Management and Biobrit ... Joe Zakrzewski , the $1.5 million financing positions SiteOne ... for pain and to further develop its technology platform ... indications. In conjunction with the financing, ...
(Date:9/23/2014)...   COTA, Inc. today announced it has ... A funding round led by Horizon Healthcare Services, Inc. ... big data platform designed by practicing oncologists to deliver ... care in support of healthcare,s new value-based reimbursement model. ... of the COTA platform, hire biostatisticians, outcome analysts, data ...
(Date:9/23/2014)... , Sept. 23, 2014  While proton therapy recently began in the ... Ashya King , another case in the United States ... a young boy who was given just days to live now looks ... Logan Green of Arizona complained of a ... of medical treatments that will conclude Sept. 23, when he completes ...
Breaking Medicine Technology:SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 2SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 45-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 25-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 35-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 4
... Pervasis Therapeutics, Inc. today announced that it has ... government,s Qualifying Therapeutic Discovery Project, which provides tax credits ... produce new therapies, reduce long-term health care costs, or ... next 30 years.   Pervasis is a ...
... 4, 2010 The physicians of Westside Medical Associates ... Beverly Hills , California have announced the results of a ... CT scans save lives.  According to Drs. Norman ... Medical Imaging, this study should once and for all settle ...
Cached Medicine Technology:Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project 2Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project 3Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project 4Annual CT Lung Screening Saves Lives 2
(Date:9/23/2014)... first year follow a set of predictable steps ... first words. However, previous research had not addressed ... hearing and deaf infants. Now, University of Missouri ... by infants, ability to hear their own babbling. ... cochlear implants to help correct their hearing soon ...
(Date:9/23/2014)... PITTSBURGH, PA (PRWEB) September 23, 2014 "The ... and infection control," said an inventor from Sacramento, Ca.. "Call ... patient bedding or left hanging on the IV pole out ... patients have the nurse call device whenever they need it, ... CADDY to effectively position the nurse call device within easy ...
(Date:9/23/2014)... CONVENE PATHWAYS TO PREVENTION WORKSHOP: ROLE OF OPIOIDS IN ... , The National Institutes of Health is convening a ... evidence on the long-term effectiveness and potential risks of ... the nation,s top experts in the field of pain ... as key NIH scientists who focus on pain related ...
(Date:9/23/2014)... September 23, 2014 World of Home ... philanthropic support. Most recently, the gym has been raising ... Fitness program. Throughout the year, World of Home Fitness ... charitable causes. , Over the summer, World of Home ... Through their Ageless Fitness program, participants helped feed seniors ...
(Date:9/23/2014)... San Diego, CA (PRWEB) September 23, 2014 ... website daily regarding all the latest information from the ... announced on September 5, that its Private Label Jalapeno ... glass and small stones. Publix Jalapeno Bagels ... in the bakery department. , Taking into consideration ...
Breaking Medicine News(10 mins):Health News:Infant cooing, babbling linked to hearing ability, MU researcher finds 2Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 2Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 3Health News:World of Home Fitness Supports Meals on Wheels 2Health News:Publix Private Label Jalapeno Bagels Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2
... Aug. 31 Endo Pharmaceuticals (Nasdaq: ENDP ) announced today that ... Sept. 10, 2009, at 2:40 p.m. EDT. Alan Levin, Chief Financial Officer ... The presentation will be webcast live and can be accessed from ... , , About Endo , ...
... , , BERWYN, Pa., Aug. 31 ... service multinational clinical research organization (CRO) conducting studies in over 30 ... today announced that on August 25, 2009, it received a letter ... its Form 10-Q for the period ended June 30, 2009, NASDAQ ...
... , , SCOTTSDALE, ... today announced that, at the Company,s 2009 Annual Meeting of Stockholders, ... an overwhelming majority all of the Company,s nominees to the board ... 63,725,589, representing approximately 56% of the 114,007,240 shares outstanding as of ...
... study, blood-thinning drug best for those at highest risk of ... patients, or those with a prior history of stroke, are ... treat atrial fibrillation, a common heart rhythm disorder, a new ... also say the drug is especially beneficial for patients with ...
... Aug. 31 (HealthDay News) -- Walk-in retail clinics staffed by ... study has found. , Writing in the Sept. 1 issue ... Dr. Ateev Mehrotra said that retail clinics -- which are ... and other retail chain stores such as Target and Wal-Mart ...
... patients choose where to get their care based on how ... at Fox Chase Cancer Center have recently documented a growing ... at high volume centers, which are generally located in metropolitan ... a study published in the Journal of Clinical Oncology ...
Cached Medicine News:Health News:Endo Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2009 2Health News:Encorium Receives NASDAQ Deficiency Letter Regarding Stockholders' Equity 2Health News:Encorium Receives NASDAQ Deficiency Letter Regarding Stockholders' Equity 3Health News:Healthcare Trust of America, Inc. Announces Results of 2009 Annual Meeting of Stockholders 2Health News:Healthcare Trust of America, Inc. Announces Results of 2009 Annual Meeting of Stockholders 3Health News:Oldest Heart Patients May Get Most From Warfarin 2Health News:Retail Medical Clinics Offer Quality Care: Study 2Health News:Retail Medical Clinics Offer Quality Care: Study 3Health News:Does the distance a patient has to travel affect where they choose to get their care? 2
... groups of flexible lighting products. The first ... three different sizes 5", 10", and 15" ... the light). These lights are for use ... ,The second group of flexible lights ...
These units, though small, still offer sufficient output to ensure current is fully adjustable from 0 to 70 mA. Instruction manual, ball electrodes, battery and leads with alligator clips are include...
... two groups of flexible lighting products. The ... in three different sizes 5", 10", and ... of the light). These lights are for ... needed., ,The second group of flexible ...
Designed to be used for neuromuscular blockage monitoring. Provides for easy placement over the ulnar nerve on a patient's wrist. Dual element permits non-invasive monitoring using a single electrode...
Medicine Products: